These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

866 related articles for article (PubMed ID: 21122498)

  • 21. Fecal calprotectin in assessing inflammatory bowel disease endoscopic activity: a diagnostic accuracy meta-analysis.
    Rokkas T; Portincasa P; Koutroubakis IE
    J Gastrointestin Liver Dis; 2018 Sep; 27(3):299-306. PubMed ID: 30240474
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Consecutive fecal calprotectin measurements for predicting relapse in pediatric Crohn's disease patients.
    Foster AJ; Smyth M; Lakhani A; Jung B; Brant RF; Jacobson K
    World J Gastroenterol; 2019 Mar; 25(10):1266-1277. PubMed ID: 30886509
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Fecal Human Neutrophil Peptide Levels Correlate with Intestinal Inflammation in Ulcerative Colitis.
    Kanmura S; Hamamoto H; Morinaga Y; Oda K; Fujita T; Arima S; Nasu Y; Sasaki F; Hashimoto S; Taguchi H; Setoyama H; Ido A
    Digestion; 2016; 93(4):300-8. PubMed ID: 27220673
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Comparison of three commercial fecal calprotectin ELISA test kits used in patients with Inflammatory Bowel Disease.
    Mirsepasi-Lauridsen HC; Bachmann Holmetoft U; Ingdam Halkjær S; Angeliki Krogfelt K; Munk Petersen A
    Scand J Gastroenterol; 2016; 51(2):211-7. PubMed ID: 26359672
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Fecal calprotectin complements routine laboratory investigations in diagnosing childhood inflammatory bowel disease.
    Quail MA; Russell RK; Van Limbergen JE; Rogers P; Drummond HE; Wilson DC; Gillett PM
    Inflamm Bowel Dis; 2009 May; 15(5):756-9. PubMed ID: 19107785
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Fecal calprotectin and lactoferrin as predictors of relapse in patients with quiescent ulcerative colitis during maintenance therapy.
    Yamamoto T; Shiraki M; Bamba T; Umegae S; Matsumoto K
    Int J Colorectal Dis; 2014 Apr; 29(4):485-91. PubMed ID: 24343276
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Usefulness of a rapid faecal calprotectin test to predict relapse in Crohn's disease patients on maintenance treatment with adalimumab.
    Ferreiro-Iglesias R; Barreiro-de Acosta M; Lorenzo-Gonzalez A; Dominguez-Muñoz JE
    Scand J Gastroenterol; 2016; 51(4):442-7. PubMed ID: 26595391
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Serum calprotectin as a biomarker for Crohn's disease.
    Meuwis MA; Vernier-Massouille G; Grimaud JC; Bouhnik Y; Laharie D; Piver E; Seidel L; Colombel JF; Louis E;
    J Crohns Colitis; 2013 Dec; 7(12):e678-83. PubMed ID: 23845231
    [TBL] [Abstract][Full Text] [Related]  

  • 29. The usefulness of fecal calprotectin in assessing inflammatory bowel disease activity.
    Lee YW; Lee KM; Lee JM; Chung YY; Kim DB; Kim YJ; Chung WC; Paik CN
    Korean J Intern Med; 2019 Jan; 34(1):72-80. PubMed ID: 29347813
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Practical fecal calprotectin cut-off value for Japanese patients with ulcerative colitis.
    Urushikubo J; Yanai S; Nakamura S; Kawasaki K; Akasaka R; Sato K; Toya Y; Asakura K; Gonai T; Sugai T; Matsumoto T
    World J Gastroenterol; 2018 Oct; 24(38):4384-4392. PubMed ID: 30344422
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Does fecal calprotectin predict short-term relapse after stopping TNFα-blocking agents in inflammatory bowel disease patients in deep remission?
    Molander P; Färkkilä M; Ristimäki A; Salminen K; Kemppainen H; Blomster T; Koskela R; Jussila A; Rautiainen H; Nissinen M; Haapamäki J; Arkkila P; Nieminen U; Kuisma J; Punkkinen J; Kolho KL; Mustonen H; Sipponen T
    J Crohns Colitis; 2015 Jan; 9(1):33-40. PubMed ID: 25052347
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Faecal calprotectin as a novel biomarker for differentiating between inflammatory bowel disease and irritable bowel syndrome.
    Chang MH; Chou JW; Chen SM; Tsai MC; Sun YS; Lin CC; Lin CP
    Mol Med Rep; 2014 Jul; 10(1):522-6. PubMed ID: 24788223
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Noninvasive Fecal Immunochemical Testing and Fecal Calprotectin Predict Mucosal Healing in Inflammatory Bowel Disease: A Prospective Cohort Study.
    Ma C; Lumb R; Walker EV; Foshaug RR; Dang TT; Verma S; Huang VW; Kroeker KI; Wong K; Dieleman LA; Fedorak RN; Halloran BP
    Inflamm Bowel Dis; 2017 Sep; 23(9):1643-1649. PubMed ID: 28644184
    [TBL] [Abstract][Full Text] [Related]  

  • 34. FECAL CALPROTECTIN: levels for the ethiological diagnosis in Brazilian patients with gastrointestinal symptoms.
    Kotze LM; Nisihara RM; Marion SB; Cavassani MF; Kotze PG
    Arq Gastroenterol; 2015; 52(1):50-4. PubMed ID: 26017083
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Development and Internal Validation of a Model Using Fecal Calprotectin in Combination with Infliximab Trough Levels to Predict Clinical Relapse in Crohn's Disease.
    Roblin X; Duru G; Williet N; Del Tedesco E; Cuilleron M; Jarlot C; Phelip JM; Boschetti G; Flourié B; Nancey S; Peyrin-Biroulet L; Paul S
    Inflamm Bowel Dis; 2017 Jan; 23(1):126-132. PubMed ID: 28002129
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Fecal calprotectin and S100A12 have low utility in prediction of small bowel Crohn's disease detected by wireless capsule endoscopy.
    Sipponen T; Haapamäki J; Savilahti E; Alfthan H; Hämäläinen E; Rautiainen H; Koskenpato J; Nuutinen H; Färkkilä M
    Scand J Gastroenterol; 2012 Jul; 47(7):778-84. PubMed ID: 22519419
    [TBL] [Abstract][Full Text] [Related]  

  • 37. High Percentage of IBD Patients with Indefinite Fecal Calprotectin Levels: Additional Value of a Combination Score.
    Bodelier AG; Jonkers D; van den Heuvel T; de Boer E; Hameeteman W; Masclee AA; Pierik MJ
    Dig Dis Sci; 2017 Feb; 62(2):465-472. PubMed ID: 27933473
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Fecal calprotectin correlates more closely with the Simple Endoscopic Score for Crohn's disease (SES-CD) than CRP, blood leukocytes, and the CDAI.
    Schoepfer AM; Beglinger C; Straumann A; Trummler M; Vavricka SR; Bruegger LE; Seibold F
    Am J Gastroenterol; 2010 Jan; 105(1):162-9. PubMed ID: 19755969
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Discontinuation of anti-tumor necrosis factor therapy in inflammatory bowel disease patients: a prospective observation.
    Bortlik M; Duricova D; Machkova N; Hruba V; Lukas M; Mitrova K; Romanko I; Bina V; Malickova K; Kolar M; Lukas M
    Scand J Gastroenterol; 2016; 51(2):196-202. PubMed ID: 26329773
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Prediction of Crohn's disease relapse with faecal calprotectin in infliximab responders: a prospective study.
    Laharie D; Mesli S; El Hajbi F; Chabrun E; Chanteloup E; Capdepont M; Razaire S; de Lédinghen V; Zerbib F
    Aliment Pharmacol Ther; 2011 Aug; 34(4):462-9. PubMed ID: 21671970
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 44.